Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasTec Inc (MTZ) vs Viatris Inc (VTRS) Price & Performance

MasTec IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

MasTec Inc vs Viatris Inc — how do they compare? MasTec Inc trades at $350.55 (market cap $26.60B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: MasTec Inc is the larger of the two by market cap, and Viatris Inc pays a 2.83% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.

MTZVTRS
Market Cap
$26.60B$19.79B
Sector
TechnologyHealth
52-Week High
$437.51$17.39
52-Week Low
$172.51$8.74
Enterprise Value
$29.34B$32.00B
Dividend Yield
2.83%

Returns comparison

Trailing returns across standard periods

About MasTec Inc

MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.

Read more on MTZ

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS